Eli Lilly and Company (NYSE:LLY) Shares Acquired by Fermata Advisors LLC

Fermata Advisors LLC grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 37.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,251 shares of the company's stock after buying an additional 338 shares during the period. Fermata Advisors LLC's holdings in Eli Lilly and Company were worth $1,033,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in LLY. Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $43,000. FPC Investment Advisory Inc. raised its holdings in Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. purchased a new position in Eli Lilly and Company during the fourth quarter valued at $48,000. Compass Financial Services Inc bought a new stake in Eli Lilly and Company during the fourth quarter valued at about $50,000. Finally, Capital A Wealth Management LLC purchased a new stake in Eli Lilly and Company in the fourth quarter worth about $63,000. Institutional investors own 82.53% of the company's stock.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Trading Up 0.6%

Shares of LLY traded up $4.32 during mid-day trading on Friday, reaching $770.00. 2,068,266 shares of the company's stock traded hands, compared to its average volume of 3,644,142. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock's 50-day moving average is $771.54 and its two-hundred day moving average is $799.67. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The stock has a market cap of $729.76 billion, a P/E ratio of 65.76, a P/E/G ratio of 1.40 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.58 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.78%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is 48.82%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on LLY shares. Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. HSBC downgraded shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their target price for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. UBS Group decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Finally, Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.